RxDoctor Payments Data

Paul Henson, MD

Urology · Crossville, TNNPI 1699722892

Payments from drug & device makers

$4,654in general payments, 2019–2025

Across 241 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$693
  • Astellas Pharma US Inc$470
  • Urovant Sciences Inc$309
  • Sumitomo Pharma America, Inc.$295
  • Urogen Pharma, Inc.$265
  • Boston Scientific$254
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,54998%
  • Education$1052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,654 in reported general payments places this provider in the 55th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$157,824
Medicare patients
437
Services billed
8,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron116$73,362
MyrbetriqMirabegron30$17,915
Finasteride357$5,717
Tamsulosin Hcl356$5,099
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst78$2,794
Solifenacin Succinate15$2,782
Methenamine Hippurate52$2,766
Trimethoprim23$2,270
Bicalutamide42$1,717
Potassium Citrate ErPotassium Citrate11$1,501
Estradiol22$1,141
Oxybutynin Chloride ErOxybutynin Chloride32$869
Dutasteride17$561
Testosterone Cypionate14$476
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim64$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$295$73,362116 claims
Astellas Pharma US IncMyrbetriq$470$17,91530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 276 urology providers in Tennessee.

Other urology in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →